Shop

Author at Microdose

Jason Najum

Jason Najum's work has appeared in many industry-leading publications, covering topics ranging from cleantech start-ups to travel and culture. He's currently Microdose's Managing Editor and Senior Writer. Write him at jason@microdose.buzz and see his work at www.jasonnajum.com

Breaking News

21 Feb 2022

Cathie Wood and ARK Increase Support for Psychedelics

ARKG has increased their investment approx 4-fold, buying ATAI an additional 4 times and bringing their total to over 340,000 shares (approx $2 million at current value)....

By Jason Najum

Breaking News, Science

16 Feb 2022

Johns Hopkins Study Shows Psilocybin Effective for a Year

A new study by Johns Hopkins Medicine shows that the antidepressant effects of psilocybin (with psychotherapy) can last at least a year after treatment....

By Jason Najum

Industry

16 Feb 2022

PharmaTher Receives U.S. Patent For Ketamine

Today the company announced that it’s been granted a new patent for the combination of FDA-approved ketamine and PharmaTher’s proprietary betaine anhydrous (“KETABET™”)....

By Jason Najum

Breaking News, Industry

15 Feb 2022

Cybin Inks Deal w Chopra Foundation. Gets Praise From Tony Robbins

The partnership with Chopra will help the sector and in particular, Cybin, who will benefit from the association with this headline name....

By Jason Najum

Join Our Newsletter for Exclusive Updates, Stories, and More

Breaking News

10 Feb 2022

Star Investor Cathie Wood Finally Buys Into Psychedelics

ARK Genomic Revolution ETF bought 83,278 shares of atai Life Sciences, its first foray into psychedelics....

By Jason Najum

Breaking News, Industry

9 Feb 2022

Cybin Granted DMT Patent for CYB004

Developing and securing intellectual property is one of the most important tasks of a psychedelic medicine firm....

By Jason Najum

Industry

8 Feb 2022

A Look at Small Pharma’s Financial and Business Highlights

Small Pharma, much to its name, has been quietly establishing itself in the psychedelic medicine space....

By Jason Najum

Don’t Miss

7 Feb 2022

News You Might Have Missed: Feb 7th, 2022

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news items to help you catch up and stay informed....

By Jason Najum

Breaking News, Law & Politics

4 Feb 2022

Breaking News: Health Canada Denies Psilocybin Access

The federal government has just denied dozens of health care professionals seeking psilocybin access and training under section 56 exemption application....

By Jason Najum

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.